Cargando…

Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors – a single Brazilian center experience

OBJECTIVE: The aim of this study was to describe the real-world experience multikinase inhibitors (MKI) in the treatment advanced differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAIR) therapy. SUBJECTS AND METHODS: We reviewed the records of all patients with MKI-treated DTC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Treistman, Natalia, Nobre, Gabriela Maia, Tramontin, Mariana Yoshii, da Silva, Gabriel Madeira Werberich, Herchenhorn, Daniel, Araujo, Luiz Henrique de Lima, de Andrade, Fernanda Accioly, Corbo, Rossana, Bulzico, Daniel, Vaisman, Fernanda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Endocrinologia e Metabologia 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522180/ https://www.ncbi.nlm.nih.gov/pubmed/33939907 http://dx.doi.org/10.20945/2359-3997000000364

Ejemplares similares

Pregnancy has no significant impact on the prognosis of differentiated thyroid cancer
por: Nobre, Gabriela Maia, et al.
Publicado: (2021)

Puberty and sex in pediatric thyroid cancer: could expression of estrogen and progesterone receptors affect prognosis?
por: da Silva Breder, Julia Ramalho Amalio, et al.
Publicado: (2022)

Cholestatic syndrome as initial manifestation of pancreatic metastasis of papillary thyroid carcinoma: case report and review
por: Tramontin, Mariana Yoshii, et al.
Publicado: (2020)

Metastatic lymph node characteristics as predictors of recurrence/persistence in the neck and distant metastases in differentiated thyroid cancer
por: Barbosa, Mayara Peres, et al.
Publicado: (2017)

Prognostic factors of a good response to initial therapy in children and adolescents with differentiated thyroid cancer
por: Vaisman, Fernanda, et al.
Publicado: (2011)

Thyroid Carcinoma in Children and Adolescents—Systematic Review of the Literature
por: Vaisman, Fernanda, et al.
Publicado: (2011)

Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm
por: Vaisman, Fernanda, et al.
Publicado: (2013)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
por: Súss, Shirlei Kugler Aiçar, et al.
Publicado: (2018)

Computed tomography findings in a Brazilian cohort of 48 patients with pneumonia due to coronavirus disease
por: Werberich, Gabriel Madeira, et al.
Publicado: (2020)

Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer
por: Andrade, Fernanda, et al.
Publicado: (2019)

Is radioactive iodine- ( 131 ) treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?
por: de Souza, Marcelo Cruzick, et al.
Publicado: (2015)

Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma
por: Nava, Carla Fernanda, et al.
Publicado: (2019)

Daily Management of Patients on Multikinase Inhibitors’ Treatment
por: Colombo, Carla, et al.
Publicado: (2022)

Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
por: Coelho, Rafael Corrêa, et al.
Publicado: (2016)

Thyroid nodules ≤ 1 cm and papillary thyroid microcarcinomas: Brazilian experts opinion
por: Rosario, Pedro Weslley, et al.
Publicado: (2019)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Timing of multikinase inhibitor initiation in differentiated thyroid cancer
por: Brose, Marcia S, et al.
Publicado: (2017)

Investigation into Brazilian Palygorskite for Its Potential Use as Pharmaceutical Excipient: Perspectives and Applications
por: Meirelles, Lyghia Maria Araújo, et al.
Publicado: (2023)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Inositol polyphosphate multikinase signaling in the regulation of metabolism
por: Lee, Joo-Young, et al.
Publicado: (2012)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez, Cesar A, et al.
Publicado: (2012)

Exploring Selectivity of Multikinase Inhibitors across the Human Kinome
por: Miljković, Filip, et al.
Publicado: (2018)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
por: Lin, Tong, et al.
Publicado: (2017)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Gastrointestinal Tract Homeostasis: The Role of the Inositol Polyphosphate Multikinase
por: Saiardi, Adolfo
Publicado: (2022)

Lung Cancer and the COVID-19 pandemic: Recommendations from the Brazilian Thoracic Oncology Group
por: Baldotto, Clarissa, et al.
Publicado: (2020)

Do Brazilian medical journals reference Brazilian articles? A cross-sectional study
por: Tramontin, Daniela Ferreira, et al.
Publicado: (2022)

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
por: Konecny, G E, et al.
Publicado: (2009)

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic, Neda, et al.
Publicado: (2014)

Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
por: Eaby-Sandy, Beth, et al.
Publicado: (2012)

Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib
por: Pan, Hongming, et al.
Publicado: (2014)

Clinically relevant drug interactions with multikinase inhibitors: a review
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2019)

The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension
por: Uschner, Frank Erhard, et al.
Publicado: (2018)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

The Expanding Significance of Inositol Polyphosphate Multikinase as a Signaling Hub
por: Kim, Eunha, et al.
Publicado: (2017)

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
por: Strasma, Anna, et al.
Publicado: (2021)

E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib
por: Bougen-Zhukov, Nicola, et al.
Publicado: (2022)

Inositol Polyphosphate Multikinase Signaling: Multifaceted Functions in Health and Disease
por: Lee, Boah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vnsmkeqpp2g6toh88qkcf3j6cq